<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39460356</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-393X</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>18</Day></PubDate></JournalIssue><Title>Vaccines</Title><ISOAbbreviation>Vaccines (Basel)</ISOAbbreviation></Journal><ArticleTitle>Intranasal Prime-Boost with Spike Vectors Generates Antibody and T-Cell Responses at the Site of SARS-CoV-2 Infection.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1191</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/vaccines12101191</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Long-lived, re-activatable immunity to SARS-CoV-2 and its emerging variants will rely on T cells recognizing conserved regions of viral proteins across strains. Heterologous prime-boost regimens can elicit elevated levels of circulating CD8+ T cells that provide a reservoir of first responders upon viral infection. Although most vaccines are currently delivered intramuscularly (IM), the initial site of infection is the nasal cavity.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Here, we tested the hypothesis that a heterologous prime and boost vaccine regimen delivered intranasally (IN) will generate improved immune responses locally at the site of virus infection compared to intramuscular vaccine/booster regimens.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In a transgenic human ACE2 murine model, both a Spike-expressing single-cycle adenovirus (SC-Ad) and an IFNß safety-enhanced replication-competent Vesicular Stomatitis Virus (VSV) platform generated anti-Spike antibody and T-cell responses that diminished with age. Although SC-Ad-Spike boosted a prime with VSV-Spike-mIFNß, SC-Ad-Spike alone induced maximal levels of IgG, IgA, and CD8+ T-cell responses.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">There were significant differences in T-cell responses in spleens compared to lungs, and the intranasal boost was significantly superior to the intramuscular boost in generating sentinel immune effectors at the site of the virus encounter in the lungs. These data show that serious consideration should be given to intranasal boosting with anti-SARS-CoV-2 vaccines.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Metko</LastName><ForeName>Muriel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Molecular Medicine, Mayo Clinic, Rochester, MN 55905, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tonne</LastName><ForeName>Jason</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Molecular Medicine, Mayo Clinic, Rochester, MN 55905, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Veliz Rios</LastName><ForeName>Alexa</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Molecular Medicine, Mayo Clinic, Rochester, MN 55905, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thompson</LastName><ForeName>Jill</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-5005-7257</Identifier><AffiliationInfo><Affiliation>Department of Molecular Medicine, Mayo Clinic, Rochester, MN 55905, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mudrick</LastName><ForeName>Haley</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Molecular Pharmacology and Experimental Therapeutics Program, Mayo Clinic, Rochester, MN 55905, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masopust</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Microbiology &amp; Immunology, University of Minnesota Medical School, 2101 6th St. SE, Minneapolis, MN 55455, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Diaz</LastName><ForeName>Rosa Maria</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Department of Molecular Medicine, Mayo Clinic, Rochester, MN 55905, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barry</LastName><ForeName>Michael A</ForeName><Initials>MA</Initials><Identifier Source="ORCID">0000-0002-8568-5664</Identifier><AffiliationInfo><Affiliation>Department of Molecular Medicine, Mayo Clinic, Rochester, MN 55905, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infectious Diseases, Mayo Clinic, Rochester, MN 55905, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Immunology, Mayo Clinic, Rochester, MN 55905, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vile</LastName><ForeName>Richard G</ForeName><Initials>RG</Initials><AffiliationInfo><Affiliation>Department of Molecular Medicine, Mayo Clinic, Rochester, MN 55905, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Immunology, Mayo Clinic, Rochester, MN 55905, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>1R01AI170535-02A1</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1R01CA269384-02A1</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>3P50CA210964-06A1</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Vaccines (Basel)</MedlineTA><NlmUniqueID>101629355</NlmUniqueID><ISSNLinking>2076-393X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">intranasal vaccine</Keyword><Keyword MajorTopicYN="N">prime–boost</Keyword><Keyword MajorTopicYN="N">viral vector</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>9</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>10</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>1</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39460356</ArticleId><ArticleId IdType="pmc">PMC11511174</ArticleId><ArticleId IdType="doi">10.3390/vaccines12101191</ArticleId><ArticleId IdType="pii">vaccines12101191</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>GeurtsvanKessel C.H., Geers D., Schmitz K.S., Mykytyn A.Z., Lamers M.M., Bogers S., Scherbeijn S., Gommers L., Sablerolles R.S.G., Nieuwkoop N.N., et al. Divergent SARS-CoV-2 Omicron-reactive T and B cell responses in COVID-19 vaccine recipients. Sci. Immunol. 2022;7:eabo2202. doi: 10.1126/sciimmunol.abo2202.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abo2202</ArticleId><ArticleId IdType="pmc">PMC8939771</ArticleId><ArticleId IdType="pubmed">35113647</ArticleId></ArticleIdList></Reference><Reference><Citation>Naranbhai V., Nathan A., Kaseke C., Berrios C., Khatri A., Choi S., Getz M.A., Tano-Menka R., Ofoman O., Gayton A., et al. T cell reactivity to the SARS-CoV-2 Omicron variant is preserved in most but not all individuals. Cell. 2022;185:1041–1051. doi: 10.1016/j.cell.2022.01.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.01.029</ArticleId><ArticleId IdType="pmc">PMC8810349</ArticleId><ArticleId IdType="pubmed">35202566</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobsen H., Jiménez V.C., Sitaras I., Bar-Zeev N., Čičin-Šain L., Higdon M.M., Deloria-Knoll M. Post-vaccination T cell immunity to omicron. Front. Immunol. 2022;13:944713. doi: 10.3389/fimmu.2022.944713.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.944713</ArticleId><ArticleId IdType="pmc">PMC9386871</ArticleId><ArticleId IdType="pubmed">35990661</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu S. Heterologous prime-boost vaccination. Curr. Opin. Immunol. 2009;21:346–351. doi: 10.1016/j.coi.2009.05.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coi.2009.05.016</ArticleId><ArticleId IdType="pmc">PMC3743086</ArticleId><ArticleId IdType="pubmed">19500964</ArticleId></ArticleIdList></Reference><Reference><Citation>Venkatraman N., Ndiaye B.P., Bowyer G., Wade D., Sridhar S., Wright D., Powlson J., Ndiaye I., Dièye S., Thompson C., et al. Safety and Immunogenicity of a Heterologous Prime-Boost Ebola Virus Vaccine Regimen in Healthy Adults in the United Kingdom and Senegal. J. Infect. Dis. 2019;219:1187–1197. doi: 10.1093/infdis/jiy639.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiy639</ArticleId><ArticleId IdType="pmc">PMC6452431</ArticleId><ArticleId IdType="pubmed">30407513</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X., Shaw R.H., Stuart A.S.V., Greenland M., Aley P.K., Andrews N.J., Cameron J.C., Charlton S., Clutterbuck E., Collins A.M., et al. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): A single-blind, randomised, non-inferiority trial. Lancet. 2021;398:856–869. doi: 10.1016/S0140-6736(21)01694-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)01694-9</ArticleId><ArticleId IdType="pmc">PMC8346248</ArticleId><ArticleId IdType="pubmed">34370971</ArticleId></ArticleIdList></Reference><Reference><Citation>Cauley L.S., Lefrançois L. Guarding the perimeter: Protection of the mucosa by tissue-resident memory T cells. Mucosal Immunol. 2012;6:14–23. doi: 10.1038/mi.2012.96.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mi.2012.96</ArticleId><ArticleId IdType="pmc">PMC4034055</ArticleId><ArticleId IdType="pubmed">23131785</ArticleId></ArticleIdList></Reference><Reference><Citation>Matchett W.E., Anguiano-Zarate S.S., Nehete P.N., Shelton K., Nehete B.P., Yang G., Dorta-Estremera S., Barnette P., Xiao P., Byrareddy S.N., et al. Divergent HIV-1-Directed Immune Responses Generated by Systemic and Mucosal Immunization with Replicating Single-Cycle Adenoviruses in Rhesus Macaques. J. Virol. 2019;93:10–1128. doi: 10.1128/JVI.02016-18.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02016-18</ArticleId><ArticleId IdType="pmc">PMC6498041</ArticleId><ArticleId IdType="pubmed">30842321</ArticleId></ArticleIdList></Reference><Reference><Citation>Matchett W.E., Malewana G.B.R., Mudrick H., Medlyn M.J., Barry M.A. Genetic Adjuvants in Replicating Single-Cycle Adenovirus Vectors Amplify Systemic and Mucosal Immune Responses against HIV-1 Envelope. Vaccines. 2020;8:64. doi: 10.3390/vaccines8010064.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines8010064</ArticleId><ArticleId IdType="pmc">PMC7158672</ArticleId><ArticleId IdType="pubmed">32024265</ArticleId></ArticleIdList></Reference><Reference><Citation>Weaver E.A., Nehete P.N., Nehete B.P., Yang G., Buchl S.J., Hanley P.W., Palmer D., Montefiori D.C., Ferrari G., Ng P., et al. Comparison of systemic and mucosal immunization with helper-dependent adenoviruses for vaccination against mucosal challenge with SHIV. PLoS ONE. 2013;8:e67574. doi: 10.1371/journal.pone.0067574.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0067574</ArticleId><ArticleId IdType="pmc">PMC3701068</ArticleId><ArticleId IdType="pubmed">23844034</ArticleId></ArticleIdList></Reference><Reference><Citation>Correa V.A., Portilho A.I., De Gaspari E. Vaccines, adjuvants and key factors for mucosal immune response. Immunology. 2022;167:124–138. doi: 10.1111/imm.13526.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imm.13526</ArticleId><ArticleId IdType="pubmed">35751397</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanaparthy R., Mohan G., Vasireddy D., Atluri P. Review of COVID-19 viral vector-based vaccines and COVID-19 variants. Le Infez. Med. 2021;29:328–338. doi: 10.53854/liim-2903-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.53854/liim-2903-3</ArticleId><ArticleId IdType="pmc">PMC8805485</ArticleId><ArticleId IdType="pubmed">35146337</ArticleId></ArticleIdList></Reference><Reference><Citation>Mudrick H.E., Massey S., McGlinch E.B., Parrett B.J., Hemsath J.R., Barry M.E., Rubin J.D., Uzendu C., Hansen M.J., Erskine C.L., et al. Comparison of replicating and nonreplicating vaccines against SARS-CoV-2. Sci. Adv. 2022;8:eabm8563. doi: 10.1126/sciadv.abm8563.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.abm8563</ArticleId><ArticleId IdType="pmc">PMC9401629</ArticleId><ArticleId IdType="pubmed">36001674</ArticleId></ArticleIdList></Reference><Reference><Citation>Crosby C.M., Barry M.A. IIIa deleted adenovirus as a single-cycle genome replicating vector. Virology. 2014;462:158–165. doi: 10.1016/j.virol.2014.05.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2014.05.030</ArticleId><ArticleId IdType="pmc">PMC4125442</ArticleId><ArticleId IdType="pubmed">24996029</ArticleId></ArticleIdList></Reference><Reference><Citation>Crosby C.M., Barry M.A. Transgene Expression and Host Cell Responses to Replication-Defective, Single-Cycle, and Replication-Competent Adenovirus Vectors. Genes. 2017;8:79. doi: 10.3390/genes8020079.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/genes8020079</ArticleId><ArticleId IdType="pmc">PMC5333068</ArticleId><ArticleId IdType="pubmed">28218713</ArticleId></ArticleIdList></Reference><Reference><Citation>Crosby C.M., Nehete P., Sastry K.J., Barry M.A. Amplified and persistent immune responses generated by single-cycle replicating adenovirus vaccines. J. Virol. 2015;89:669–675. doi: 10.1128/JVI.02184-14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02184-14</ArticleId><ArticleId IdType="pmc">PMC4301142</ArticleId><ArticleId IdType="pubmed">25355873</ArticleId></ArticleIdList></Reference><Reference><Citation>Matchett W.E., Anguiano-Zarate S.S., Barry M.A. Comparison of systemic and mucosal immunization with replicating Single cycle Adenoviruses. Glob. Vaccines Immunol. 2018;3 doi: 10.15761/GVI.1000128.</Citation><ArticleIdList><ArticleId IdType="doi">10.15761/GVI.1000128</ArticleId><ArticleId IdType="pmc">PMC6368267</ArticleId><ArticleId IdType="pubmed">30740532</ArticleId></ArticleIdList></Reference><Reference><Citation>Regules J.A., Beigel J.H., Paolino K.M., Voell J., Castellano A.R., Hu Z., Muñoz P., Moon J.E., Ruck R.C., Bennett J.W., et al. A Recombinant Vesicular Stomatitis Virus Ebola Vaccine. N. Engl. J. Med. 2017;376:330–341. doi: 10.1056/NEJMoa1414216.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1414216</ArticleId><ArticleId IdType="pmc">PMC5408576</ArticleId><ArticleId IdType="pubmed">25830322</ArticleId></ArticleIdList></Reference><Reference><Citation>Woolsey C., Geisbert T.W. Current state of Ebola virus vaccines: A snapshot. PLoS Pathog. 2021;17:e1010078. doi: 10.1371/journal.ppat.1010078.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1010078</ArticleId><ArticleId IdType="pmc">PMC8659338</ArticleId><ArticleId IdType="pubmed">34882741</ArticleId></ArticleIdList></Reference><Reference><Citation>Suder E., Furuyama W., Feldmann H., Marzi A., de Wit E. The vesicular stomatitis virus-based Ebola virus vaccine: From concept to clinical trials. Hum. Vaccines Immunother. 2018;14:2107–2113. doi: 10.1080/21645515.2018.1473698.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2018.1473698</ArticleId><ArticleId IdType="pmc">PMC6183239</ArticleId><ArticleId IdType="pubmed">29757706</ArticleId></ArticleIdList></Reference><Reference><Citation>Case J.B., Rothlauf P.W., Chen R.E., Liu Z., Zhao H., Kim A.S., Bloyet L.M., Zeng Q., Tahan S., Droit L., et al. Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2. Cell Host Microbe. 2020;28:475–485. doi: 10.1016/j.chom.2020.06.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2020.06.021</ArticleId><ArticleId IdType="pmc">PMC7332453</ArticleId><ArticleId IdType="pubmed">32735849</ArticleId></ArticleIdList></Reference><Reference><Citation>Dieterle M.E., Haslwanter D., Bortz R.H., 3rd, Wirchnianski A.S., Lasso G., Vergnolle O., Abbasi S.A., Fels J.M., Laudermilch E., Florez C., et al. A Replication-Competent Vesicular Stomatitis Virus for Studies of SARS-CoV-2 Spike-Mediated Cell Entry and Its Inhibition. Cell Host Microbe. 2020;28:486–496. doi: 10.1016/j.chom.2020.06.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2020.06.020</ArticleId><ArticleId IdType="pmc">PMC7332447</ArticleId><ArticleId IdType="pubmed">32738193</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt F., Weisblum Y., Muecksch F., Hoffmann H.H., Michailidis E., Lorenzi J.C.C., Mendoza P., Rutkowska M., Bednarski E., Gaebler C., et al. Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. J. Exp. Med. 2020;21:e20201181. doi: 10.1084/jem.20201181.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20201181</ArticleId><ArticleId IdType="pmc">PMC7372514</ArticleId><ArticleId IdType="pubmed">32692348</ArticleId></ArticleIdList></Reference><Reference><Citation>Sterlin D., Mathian A., Miyara M., Mohr A., Anna F., Claër L., Quentric P., Fadlallah J., Devilliers H., Ghillani P., et al. IgA dominates the early neutralizing antibody response to SARS-CoV-2. Sci. Transl. Med. 2021;13:eabd2223. doi: 10.1126/scitranslmed.abd2223.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abd2223</ArticleId><ArticleId IdType="pmc">PMC7857408</ArticleId><ArticleId IdType="pubmed">33288662</ArticleId></ArticleIdList></Reference><Reference><Citation>Koutsakos M., Turner J.S., Guillamet M.C.V., Reynolds D., Lei T., Byers D., Ellebedy A.H., Mudd P. Assessment of antibodies in the upper and lower human respiratory tract at steady state and after respiratory viral infection. Clin. Transl. Immunol. 2023;12:e1460. doi: 10.1002/cti2.1460.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cti2.1460</ArticleId><ArticleId IdType="pmc">PMC10410120</ArticleId><ArticleId IdType="pubmed">37564999</ArticleId></ArticleIdList></Reference><Reference><Citation>Adler J.M., Martin Vidal R., Langner C., Vladimirova D., Abdelgawad A., Kunecova D., Lin X., Nouailles G., Voss A., Kunder S., et al. An intranasal live-attenuated SARS-CoV-2 vaccine limits virus transmission. Nat. Commun. 2024;15:995. doi: 10.1038/s41467-024-45348-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-024-45348-2</ArticleId><ArticleId IdType="pmc">PMC10837132</ArticleId><ArticleId IdType="pubmed">38307868</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhama K., Dhawan M., Tiwari R., Bin Emran T., Mitra S., Rabaan A.A., Alhumaid S., Al Alawi Z., Al Mutair A. COVID-19 intranasal vaccines: Current progress, advantages, prospects, and challenges. Hum. Vaccines Immunother. 2022;18:2045853. doi: 10.1080/21645515.2022.2045853.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2022.2045853</ArticleId><ArticleId IdType="pmc">PMC8935456</ArticleId><ArticleId IdType="pubmed">35258416</ArticleId></ArticleIdList></Reference><Reference><Citation>Willmon C., Diaz R.M., Wongthida P., Galivo F., Kottke T., Thompson J., Albelda S., Harrington K., Melcher A., Vile R. Vesicular stomatitis virus-induced immune suppressor cells generate antagonism between intratumoral oncolytic virus and cyclophosphamide. Mol. Ther. 2011;19:140–149. doi: 10.1038/mt.2010.224.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mt.2010.224</ArticleId><ArticleId IdType="pmc">PMC3017451</ArticleId><ArticleId IdType="pubmed">20978474</ArticleId></ArticleIdList></Reference><Reference><Citation>Willmon C.L., Saloura V., Fridlender Z.G., Wongthida P., Diaz R.M., Thompson J., Kottke T., Federspiel M., Barber G., Albelda S.M., et al. Expression of IFN-beta enhances both efficacy and safety of oncolytic vesicular stomatitis virus for therapy of mesothelioma. Caner Res. 2009;69:7713–7720. doi: 10.1158/0008-5472.CAN-09-1013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-09-1013</ArticleId><ArticleId IdType="pmc">PMC3891512</ArticleId><ArticleId IdType="pubmed">19773437</ArticleId></ArticleIdList></Reference><Reference><Citation>Wongthida P., Diaz R.M., Galivo F., Kottke T., Thompson J., Melcher A., Vile R. VSV oncolytic virotherapy in the B16 model depends upon intact MyD88 signaling. Mol. Ther. 2011;19:150–158. doi: 10.1038/mt.2010.225.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mt.2010.225</ArticleId><ArticleId IdType="pmc">PMC3017452</ArticleId><ArticleId IdType="pubmed">20959810</ArticleId></ArticleIdList></Reference><Reference><Citation>Stojdl D.F., Lichty B., Knowles S., Marius R., Atkins H., Sonenberg N., Bell J.C. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat. Med. 2000;6:821–825. doi: 10.1038/77558.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/77558</ArticleId><ArticleId IdType="pubmed">10888934</ArticleId></ArticleIdList></Reference><Reference><Citation>Stojdl D.F., Lichty B.D., Tenoever B.R., Paterson J.M., Power A.T., Knowles S., Marius R., Reynard J., Poliquin L., Atkins H., et al. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell. 2003;4:263–275. doi: 10.1016/S1535-6108(03)00241-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1535-6108(03)00241-1</ArticleId><ArticleId IdType="pubmed">14585354</ArticleId></ArticleIdList></Reference><Reference><Citation>Obuchi M., Fernandez M., Barber G.N. Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity. J. Virol. 2003;77:8843–8856. doi: 10.1128/JVI.77.16.8843-8856.2003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.77.16.8843-8856.2003</ArticleId><ArticleId IdType="pmc">PMC167243</ArticleId><ArticleId IdType="pubmed">12885903</ArticleId></ArticleIdList></Reference><Reference><Citation>Jenks N., Myers R., Greiner S.M., Thompson J., Mader E.K., Greenslade A., Griesmann G.E., Federspiel M.J., Rakela J., Borad M.J., et al. Safety studies on intrahepatic or intratumoral injection of oncolytic vesicular stomatitis virus expressing interferon-beta in rodents and nonhuman primates. Hum. Gene Ther. 2010;21:451–462. doi: 10.1089/hum.2009.111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/hum.2009.111</ArticleId><ArticleId IdType="pmc">PMC2865219</ArticleId><ArticleId IdType="pubmed">19911974</ArticleId></ArticleIdList></Reference><Reference><Citation>Durham N.M., Mulgrew K., McGlinchey K., Monks N.R., Ji H., Herbst R., Suzich J., Hammond S.A., Kelly E.J. Oncolytic VSV Primes Differential Responses to Immuno-oncology Therapy. Mol. Ther. 2017;25:1917–1932. doi: 10.1016/j.ymthe.2017.05.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2017.05.006</ArticleId><ArticleId IdType="pmc">PMC5542805</ArticleId><ArticleId IdType="pubmed">28578991</ArticleId></ArticleIdList></Reference><Reference><Citation>Anguiano-Zarate S.S., Matchett W., Nehete P.N., Sastry J.K., Marzi A., Barry M. A Replicating Single-Cycle Adenovirus Vaccine Against Ebola Virus. J. Infect. Dis. 2018;218:1883–1889. doi: 10.1093/infdis/jiy411.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiy411</ArticleId><ArticleId IdType="pmc">PMC6217725</ArticleId><ArticleId IdType="pubmed">29982595</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyaka P.N. Inducing Mucosal IgA: A Challenge for Vaccine Adjuvants and Delivery Systems. J. Immunol. 2017;199:9–16. doi: 10.4049/jimmunol.1601775.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1601775</ArticleId><ArticleId IdType="pmc">PMC5719502</ArticleId><ArticleId IdType="pubmed">28630108</ArticleId></ArticleIdList></Reference><Reference><Citation>McBride C.E., Li J., Machamer C.E. The cytoplasmic tail of the severe acute respiratory syndrome coronavirus spike protein contains a novel endoplasmic reticulum retrieval signal that binds COPI and promotes interaction with membrane protein. J. Virol. 2007;81:2418–2428. doi: 10.1128/JVI.02146-06.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02146-06</ArticleId><ArticleId IdType="pmc">PMC1865919</ArticleId><ArticleId IdType="pubmed">17166901</ArticleId></ArticleIdList></Reference><Reference><Citation>Whelan S.P., Ball L., Barr J.N., Wertz G.T. Efficient recovery of infectious vesicular stomatitis virus entirely from cDNA clones. Proc. Natl. Acad. Sci. USA. 1995;92:8388–8392. doi: 10.1073/pnas.92.18.8388.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.92.18.8388</ArticleId><ArticleId IdType="pmc">PMC41162</ArticleId><ArticleId IdType="pubmed">7667300</ArticleId></ArticleIdList></Reference><Reference><Citation>Schnell M.J., Buonocore L., Whitt M., Rose J.K. The minimal conserved transcription stop-start signal promotes stable expression of a foreign gene in vesicular stomatitis virus. J. Virol. 1996;70:2318–2323. doi: 10.1128/jvi.70.4.2318-2323.1996.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.70.4.2318-2323.1996</ArticleId><ArticleId IdType="pmc">PMC190073</ArticleId><ArticleId IdType="pubmed">8642658</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahy B.W.J., Kangro H.O. Virology Methods Manual. Academic Press; San Diego, CA, USA: 1996.</Citation></Reference><Reference><Citation>Spearman C. The method of “Right and Wrong Cases” (Constant Stimuli) without Gauss’s formulae. Br. J. Psychol. 1908;2:227–242. doi: 10.1111/j.2044-8295.1908.tb00176.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.2044-8295.1908.tb00176.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Kärber G. Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche. Arch. Exp. Pathol. Pharmakol. 1931;162:480–483. doi: 10.1007/BF01863914.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF01863914</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurisetty V.V.S., Heiber J., Myers R., Pereira G.S., Goodwin J.W., Federspiel M.J., Russell S.J., Peng K.W., Barber G., Merchan J.R. Preclinical safety and activity of recombinant VSV-IFN-β in an immunocompetent model of squamous cell carcinoma of the head and neck. Head Neck. 2014;36:1619–1627. doi: 10.1002/hed.23502.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hed.23502</ArticleId><ArticleId IdType="pmc">PMC3969865</ArticleId><ArticleId IdType="pubmed">24115092</ArticleId></ArticleIdList></Reference><Reference><Citation>Saloura V., Wang L.-C.S., Fridlender Z.G., Sun J., Cheng G., Kapoor V., Sterman D.H., Harty R.N., Okumura A., Barber G.N., et al. Evaluation of an attenuated vesicular stomatitis virus vector expressing interferon-beta for use in malignant pleural mesothelioma: Heterogeneity in interferon responsiveness defines potential efficacy. Hum. Gene Ther. 2010;21:51–64. doi: 10.1089/hum.2009.088.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/hum.2009.088</ArticleId><ArticleId IdType="pmc">PMC2829454</ArticleId><ArticleId IdType="pubmed">19715403</ArticleId></ArticleIdList></Reference><Reference><Citation>Hastie E., Grdzelishvili V.Z. Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancer. J. Gen. Virol. 2012;93:2529–2545. doi: 10.1099/vir.0.046672-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.046672-0</ArticleId><ArticleId IdType="pmc">PMC4091291</ArticleId><ArticleId IdType="pubmed">23052398</ArticleId></ArticleIdList></Reference><Reference><Citation>Pol J.G., Workenhe S.T., Konda P., Gujar S., Kroemer G. Cytokines in oncolytic virotherapy. Cytokine Growth Factor Rev. 2020;56:4–27. doi: 10.1016/j.cytogfr.2020.10.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cytogfr.2020.10.007</ArticleId><ArticleId IdType="pubmed">33183957</ArticleId></ArticleIdList></Reference><Reference><Citation>Kramer M., Dennin R., Kramer C., Jones G., Connell E., Rolon N., Gruarin A., Kale R., Trown P. Cell and virus sensitivity studies with recombinant human alpha interferons. J. Interf. Res. 1983;3:425–435. doi: 10.1089/jir.1983.3.425.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/jir.1983.3.425</ArticleId><ArticleId IdType="pubmed">6323591</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>